Pitavastatin protects against neomycin-induced ototoxicity through inhibition of endoplasmic reticulum stress.
endoplasmic reticulum stress
hair cell
hearing loss
neomycin
pitavastatin
Journal
Frontiers in molecular neuroscience
ISSN: 1662-5099
Titre abrégé: Front Mol Neurosci
Pays: Switzerland
ID NLM: 101477914
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
06
2022
accepted:
13
07
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
23
8
2022
Statut:
epublish
Résumé
Irreversible injury to inner ear hair cells induced by aminoglycoside antibiotics contributes to the formation of sensorineural hearing loss. Pitavastatin (PTV), a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has been reported to exert neuroprotective effects. However, its role in aminoglycoside-induced hearing loss remains unknown. The objectives of this study were to investigate the beneficial effects, as well as the mechanism of action of PTV against neomycin-induced ototoxicity. We found that PTV remarkably reduced hair cell loss in mouse cochlear explants and promoted auditory HEI-OC1 cells survival after neomycin stimulation. We also observed that the auditory brainstem response threshold that was increased by neomycin was significantly reduced by pretreatment with PTV in mice. Furthermore, neomycin-induced endoplasmic reticulum stress in hair cells was attenuated by PTV treatment through inhibition of PERK/eIF2α/ATF4 signaling. Additionally, we found that PTV suppressed the RhoA/ROCK/JNK signal pathway, which was activated by neomycin stimulation in HEI-OC1 cells. Collectively, our results showed that PTV might serve as a promising therapeutic agent against aminoglycoside-induced ototoxicity.
Identifiants
pubmed: 35992197
doi: 10.3389/fnmol.2022.963083
pmc: PMC9381809
doi:
Types de publication
Journal Article
Langues
eng
Pagination
963083Informations de copyright
Copyright © 2022 Wu, Meng, Guan, Zhao, Zhang, Fang, Zhang, Sun, Cai, Huang, Yang, Yu, Cui, He and Chai.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pharmacol Ther. 2012 Jun;134(3):306-16
pubmed: 22387231
Cold Spring Harb Perspect Med. 2019 Nov 1;9(11):
pubmed: 30559254
Eur J Pharmacol. 2021 Sep 15;907:174249
pubmed: 34116042
Front Immunol. 2019 Jan 04;9:3083
pubmed: 30662442
J Mol Cell Cardiol. 2020 Jun;143:15-25
pubmed: 32311415
Front Mol Biosci. 2019 Mar 12;6:11
pubmed: 30931312
Hear Res. 2020 Apr;389:107905
pubmed: 32062294
Nature. 2016 Jan 21;529(7586):326-35
pubmed: 26791723
Int J Mol Sci. 2020 Aug 25;21(17):
pubmed: 32854418
Sci Rep. 2017 Mar 09;7:44219
pubmed: 28276528
Cochrane Database Syst Rev. 2020 Jun 19;6:CD012735
pubmed: 32557581
Neural Plast. 2021 Jul 11;2021:4909237
pubmed: 34335732
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):
pubmed: 34479996
Stroke. 2021 Oct;52(10):3142-3150
pubmed: 34154390
Brain Res. 2011 Jan 31;1371:161-70
pubmed: 21112317
Science. 2006 Jul 7;313(5783):104-7
pubmed: 16825573
Neuroscience. 2011 Dec 1;197:358-68
pubmed: 21955601
Toxicol Lett. 2018 Sep 15;294:20-26
pubmed: 29751043
Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168
pubmed: 28130659
Front Immunol. 2020 Jan 08;10:2951
pubmed: 31998288
Trends Cancer. 2016 May;2(5):252-262
pubmed: 28741511
Mol Biol Cell. 2020 Nov 1;31(23):2597-2629
pubmed: 32877278
Mol Cells. 2018 Aug 31;41(8):705-716
pubmed: 30078231
Neurobiol Aging. 2020 May;89:41-54
pubmed: 31982202
Vascul Pharmacol. 2007 Apr;46(4):286-92
pubmed: 17178255
J Assoc Res Otolaryngol. 2011 Dec;12(6):729-40
pubmed: 21879401
Expert Rev Anti Infect Ther. 2012 Apr;10(4):459-73
pubmed: 22512755
BMC Neurosci. 2011 Nov 14;12:114
pubmed: 22082490
Cancer Lett. 2013 May 28;332(2):249-64
pubmed: 20732741
Neuroscience. 2012 Apr 19;208:123-32
pubmed: 22366511
Neurobiol Aging. 2012 Oct;33(10):2306-20
pubmed: 22133277
Front Cell Neurosci. 2020 Nov 17;14:572434
pubmed: 33328888
Theranostics. 2020 Jan 1;10(1):133-150
pubmed: 31903111
Neurol Res. 2018 May;40(5):391-397
pubmed: 29544396
PLoS One. 2011;6(7):e22347
pubmed: 21818312
Exp Ther Med. 2022 Feb;23(2):132
pubmed: 35069813
Science. 2011 Nov 25;334(6059):1081-6
pubmed: 22116877
Circ Res. 2017 Jan 6;120(1):229-243
pubmed: 28057795
Toxicol Appl Pharmacol. 2021 Jan 1;410:115363
pubmed: 33290780
Oncol Rep. 2021 Mar;45(3):801-808
pubmed: 33469681
Hear Res. 2022 Jan 31;:108453
pubmed: 35125240
Annu Rev Pathol. 2015;10:173-94
pubmed: 25387057
J Pineal Res. 2015 Oct;59(3):292-307
pubmed: 26201382
Brain Res. 2011 May 4;1388:32-8
pubmed: 21419111
Expert Opin Pharmacother. 2019 Jan;20(1):103-113
pubmed: 30482061
Science. 2014 Jul 4;345(6192):98-101
pubmed: 24994655